Preferred Label : Marimastat;
NCIt synonyms : (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic
Acid; (2S,3R)-3-{(S)-[2,2-Dimethyl-1-(methylcarbamoyl) propyl]carbamoyl}-2-hydroxy-5-methylhexanohydroxamic
acid; Marimistat;
NCIt related terms : BB 2516;
NCIt definition : An orally-active synthetic hydroxamate with potential antineoplastic activity. Marimastat
covalently binds to the zinc(II) ion in the active site of matrix metalloproteinases
(MMPs), thereby inhibiting the action of MMPs, inducing extracellular matrix degradation,
and inhibiting angiogenesis, tumor growth and invasion, and metastasis. This agent
may also inhibit tumor necrosis factor-alpha converting enzyme (TACE), an enzyme involved
in tumor necrosis factor alpha (TNF-alpha) production that may play a role in some
malignancies as well as in the development of arthritis and sepsis. (NCI04);
Alternative definition : NCI-GLOSS: An anticancer drug that belongs to the family of drugs called angiogenesis
inhibitors. Marimastat is a matrix metalloproteinase inhibitor.;
UNII : D5EQV23TDS;
InChIKey : OCSMOTCMPXTDND-OUAUKWLOSA-N;
CAS number : 154039-60-8;
Molecule name : TA-2516; BB-2516;
Chemical formula : C15H29N3O5;
NSC code : 689451; 719333;
ChEBI ID : CHEBI:50662;
Codes from synonyms : 31671; NSC0719333; CDR0000045473;
Origin ID : C1652;
UMLS CUI : C0338344;
Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- is_component_of_chemotherapy_regimen
